HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization (Q43917129)

From Wikidata

Jump to navigation Jump to search

scientific article published in September 2005

Language	Label	Description	Also known as
English	HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization	scientific article published in September 2005

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

John R. Mascola

13

object named as

John R Mascola

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Francine E McCutchan

9

object named as

Francine E McCutchan

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Eric Sanders-Buell

7

object named as

Eric Sanders-Buell

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

3

object named as

Elena Chertova

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

1

object named as

Mark K Louder

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

author name string

Anna Sambor

2

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Tai Hunte

4

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Sarah Barrett

5

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Fallon Ojong

6

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Susan Zolla-Pazner

8

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

James D Roser

10

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Dana Gabuzda

11

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Jeffrey D Lifson

12

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

language of work or name

0 references

publication date

1 September 2005

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

339

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

226-238

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Attachment of human immunodeficiency virus-1 (HIV-1) particles bearing host-encoded B7-2 proteins leads to nuclear factor-kappa B- and nuclear factor of activated T cells-dependent activation of HIV-1 long terminal repeat transcription

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Presence of host ICAM-1 in laboratory and clinical strains of human immunodeficiency virus type 1 increases virus infectivity and CD4(+)-T-cell depletion in human lymphoid tissue, a major site of replication in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

The importance of virus-associated host ICAM-1 in human immunodeficiency virus type 1 dissemination depends on the cellular context.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Differential incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and major histocompatibility complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: implications for viral pathogenesis and immune regulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

New insights into the functionality of a virion-anchored host cell membrane protein: CD28 versus HIV type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Insertion of host-derived costimulatory molecules CD80 (B7.1) and CD86 (B7.2) into human immunodeficiency virus type 1 affects the virus life cycle

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

LFA-1 expression on target cells promotes human immunodeficiency virus type 1 infection and transmission

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

HLA-DR, ICAM-1, CD40, CD40L, and CD86 are incorporated to a similar degree into clinical human immunodeficiency virus type 1 variants expanded in natural reservoirs such as peripheral blood mononuclear cells and human lymphoid tissue cultured ex viv

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Envelope glycoproteins are dispensable for insertion of host HLA-DR molecules within nascent human immunodeficiency virus type 1 particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Urgently needed: a filter for the HIV-1 vaccine pipeline

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Evolution of neutralizing antibody response against HIV type 1 virions and pseudovirions in multicenter AIDS cohort study participants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Presence of Host ICAM-1 in Human Immunodeficiency Virus Type 1 Virions Increases Productive Infection of CD4 + T Lymphocytes by Favoring Cytosolic Delivery of Viral Material

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Antibody neutralization and escape by HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Level of ICAM-1 surface expression on virus producer cells influences both the amount of virion-bound host ICAM-1 and human immunodeficiency virus type 1 infectivity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

Characterization of the functional properties of env genes from long-term survivors of human immunodeficiency virus type 1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibody to adhesion molecule LFA-1 enhances plasma neutralization of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

based on heuristic

inferred from DOI database lookup

Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

based on heuristic

inferred from DOI database lookup

Determinants of entry cofactor utilization and tropism in a dualtropic human immunodeficiency virus type 1 primary isolate.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

based on heuristic

inferred from DOI database lookup

Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential glycosylation, virion incorporation, and sensitivity to neutralizing antibodies of human immunodeficiency virus type 1 envelope produced from infected primary T-lymphocyte and macrophage cultures

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

based on heuristic

inferred from DOI database lookup

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.003

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2005.06.003

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43917129&oldid=2104376913"